Starting with a fully invested A-share portfolio to become a capital...

Chapter 234 Duke Zhuang of Zheng shoots the Zhou emperor with an arrow, revealing a 10-year-long deception.
If you were to ask a stock investor what they fear most, it would definitely be the accumulation of negative public opinion while they are unable to sell their stocks in time.

Why is T+1 trading constantly criticized?

1. Funds cannot be traded continuously.

Assuming you have 1 yuan, without considering transaction fees, the maximum amount of funds you can access in a day is 1 yuan.

Because once the purchase is made, this portion of the funds is essentially frozen for one day.

反观T+0交易，A股连续竞价的时间是上午9点30分到11点30分，下午是13点到14点57分，共计237分钟，也就是14220秒。

Assuming an average transaction speed of 3 seconds, a maximum of 4740 transactions can be made per day. And assuming the total amount of 1 yuan remains constant, then 1 yuan can leverage a transaction volume of 4740 million yuan.

2. Transaction lag.

Many stock investors have experienced situations where they have just bought a stock and then negative news comes out, or the market plunges and drags down their stocks.

Want to sell your stocks?

Sorry, you'll have to wait a day!
Like T+1 trading, market closures during holidays also result in trading delays, creating a sense of déjà vu.

This is why, during holidays such as the May Day holiday, the seven-day National Day holiday, the Spring Festival, and ordinary weekends, there are always debates in the stock market about whether to hold cash or stocks over the holidays.

On October 5th, the fifth day of the National Day holiday, with four days to go before the A-share market opened, the discussion on "Whether there is a path error in synthetic peptide vaccines" reached unprecedented levels of intensity, thanks to the participation of executives from drug development companies such as Qiao Lechen, He Jiani, and Bing Yaojie.

Although Shancheng Beer, Jiachen Bio, Chaos Investment, Zexi Private Equity, and a large number of vested interest groups tried to reduce the topic's popularity, things obviously didn't go as they expected.

Who had the most leisure time during the National Day holiday?
Student group!

With the first student majoring in pharmaceutical research stepping in to demonstrate the results, things began to spiral out of control.

[Anonymous Bald Student]: Yesterday, Professor Qiao Lechen said that peptide molecules have poor stability and weak immunogenicity in the human body, and are easily degraded. They cannot continuously stimulate the immune system to produce enough specific antibodies and cellular immune responses. Last night, I was thinking about whether it is possible to use molecular structure modification technology to replace L-amino acids that are easily recognized by enzymes, such as leucine and arginine, with D-amino acids or non-natural amino acids? I hope Professor Qiao Lechen can answer this question.

Before Qiao Lechen could reply, another student had already replied to him.

[No regrets in this life]: @Unknown bald student, don't just sleep in class, buddy. The binding of peptides to targets depends on precise stereoconformation. The spatial structure of D-amino acids is opposite to that of natural L-amino acids, which may disrupt this conformational match, causing the peptide to be unable to bind to the target or to have a significantly reduced binding force.

[Jack Killer]: @I have no regrets in this life. You said it was possible. Since it's not absolute, what if the stereoconformation isn't destroyed? Wouldn't that increase the stability of the peptide molecule?
[Sexy Touching]: @JackKiller, people say it might be for the sake of rigor, since there are no absolutes in scientific research. I think we can use liposomes, polymer nanoparticles, or dendritic macromolecules to encapsulate peptide molecules. The carrier shell can prevent proteases from contacting the peptide, and at the same time, through the high permeability and retention effect of the EPR effect, it can be enriched in the target tissue, reducing the clearance of non-target sites.

[I'm awesome]: @SexyCrazyTouch, I'm so confused, you silly Chun! How can a synthetic peptide vaccine use a carrier shell? You might as well say that the peptide is coupled with a polyethylene glycol antibody fragment, and its "invisibility" reduces immune clearance.

[Sexy Touching]: @I'm awesome, hahaha bro, I was still half asleep during the National Day holiday and didn't see clearly. You guys chat, you guys chat.

During the eight-day National Day holiday, students are the most relaxed, not only because they have energy, but also because their knowledge reserves are astounding.

When students majoring in pharmaceutical research get involved, the matter is no longer a simple behind-the-scenes financial game, but a pure academic discussion.

Individual buyers who had purchased Shancheng Beer were immediately disheartened upon seeing the discussions among pharmaceutical research students. Based on the available information, synthetic peptide vaccines seemed truly unreliable.

[Small Investor]: With a holding cost of 70 yuan, if the negative public opinion continues to ferment, my friends, I might really have to jump.

[Loves Dumplings]: Hahaha, let the storm rage on! You guys were laughing at us for buying blue-chip stocks a while ago, now it's your turn to suffer losses!
[Truck driver Brother Wang]: It's not easy for me to earn money, so all you little devils, calm down. Come to Jinan, I'll treat you to some fun at the shopping mall.

[Using a sledgehammer to crack a nut]: Damn you, Jiachen Biotechnology! Is your PR department dead? Why aren't you responding? And what about Shancheng Beer's PR and legal departments? Are you all dead?

Retail investors are furious. Jiachen Bio's first two responses not only failed to quell public opinion but also exposed the vaccine's defects.

At this point, the public relations department of Shancheng Beer, which was being criticized, was also helpless. They knew nothing about drug development, and even if they wanted to do emergency public relations, they were powerless. They could only wait for the synthetic peptide vaccine research and development team to give a targeted response before they could do public relations.

Unlike the public relations department, the legal department of Shancheng Beer is much busier.

Negative posts?

First report it; if that doesn't work, send a formal letter!

Negative videos?

First report it; if that doesn't work, send a formal letter!

Whenever there is even the slightest negative aspect, the legal department of Shancheng Beer will send a letter to try to narrow the scope of the dissemination.

Despite the frantic letters sent out, the discussion on "whether there is a path error in synthetic peptide vaccines" remains heated.

Students might be afraid of lawyers' letters, but executives of "competitive" companies are not.

In Qiao Lechen's opinion, a lawyer's letter is not as useful as toilet paper. If you're so capable, just issue a court summons directly, instead of all this nonsense.

Of course.

Even if you receive a summons, don't panic.

In their situation, they will most likely be sued for defamation. If they lose the case, they will only have to pay some money and publish an apology in the newspaper.

For pharmaceutical company executives like Qiao Lechen, He Jiani, and Bing Yaojie, the consequences of exposing the counterfeit Jiachen Biotechnology are entirely bearable.

……

Mountain city in Sichuan and Chongqing.

Jiangbei International Airport.

Huang Minggui, chairman of Shancheng Beer, forced a smile, waved goodbye to his wife and daughter, and said, "Have a good time in the Maldives. I have things to do at the company, so I can't go with you."

As soon as he finished speaking, a girl of about 11 years old, with a neat ponytail and wearing a yellow floral dress, said with a pained expression, "Dad, you still have to work during the National Day holiday?"

“Yes, the company has been a bit busy lately. Once things settle down, I’ll take Qiqi to Africa to see the animal migration,” Huang Minggui said affectionately.

It's said that you can travel to Southeast Asia on a budget, travel to Europe if you're rich, and only the extremely wealthy can travel to Africa.

Can you go to Africa if you don't have money?
of course can!

But all I saw was poverty and backwardness.

But if you travel to Africa with millions, or even tens of millions of dollars, you can not only experience armed bodyguards, but also get up close to wild animals and even hunt them.

The annual animal migration in Africa attracts a large number of wealthy people from all over the world to watch.

"Yay, I want to see elephants!"

Qiqi's eyebrows relaxed.

“Okay, then we’ll see not only elephants, but also lions, leopards, zebras, and lots and lots of other animals,” Huang Minggui said indulgently.

"Are there tigers? Who's stronger, a tiger or a lion?" Qiqi asked curiously.

Huang Minggui was taken aback. He really didn't know whether a lion or a tiger was more powerful, and there were no native tiger populations in Africa.

However, the West believes that lions are stronger than tigers, and games like Animal Chess, which originated under the influence of Western culture, all involve lions defeating tigers.

Liu Pingping, a woman wearing a pearl necklace and dressed elegantly, answered for Huang Minggui: "Alright, Qiqi, don't make things difficult for your father. Lions and tigers are equally powerful. We should head to the waiting area."

"Ok."

Qiqi lowered her head.

Say goodbye to your father.

Goodbye, Dad.

Goodbye, have fun.

Huang Minggui smiled broadly as he watched his wife and daughter pass through the security gate.

As soon as Liu Pingping and Qiqi disappeared from sight, Huang Minggui's smile vanished instantly, and he became extremely serious.

Without the slightest hesitation, he left the airport and returned to his Mercedes.

Instead of starting the car, Huang Minggui took out his phone and dialed the number of Shao Xia, the CEO of Jiachen Biotechnology.

Why haven't you responded promptly to the online criticisms of our vaccines?

He got straight to the point.

Huang Minggui doesn't understand vaccines or synthetic peptides, but he is Chinese, can read Chinese, and has a general understanding of the core issues at play in the current online discourse.

If he hadn't needed to take his wife and daughter to the airport, he would have driven to Shaoxia Residential Area long ago.

Shao Xia swallowed hard on the other end of the phone, her mind racing. She immediately came up with an excuse: "It's like this, Mr. Huang. It's the National Day holiday now, and there are only two people on duty in the lab. We can't contact the other staff. They probably didn't bring their work phones with them, so... that's why our response to the questions is a bit slow."

"I don't want to hear any of this. I just want to ask you one question: can you get this sorted out before the stock market opens on the 9th?"

Huang Minggui asked in a cold voice.

He originally planned to apply to the China Securities Regulatory Commission for a share issuance once the share price of Shancheng Beer reached 100 yuan. He also considered 100 yuan to be a relatively high price.

Many retail investors judge whether a stock has reached a temporary peak by looking at the relationship between volume and price. However, if there is a share issuance or the founder reduces his holdings, it is enough to determine that it is likely the top.

why would you say so?

The simplest question is: do you, as a retail investor, know more about your own company than the founders?

In addition, the core of high-level share issuance is to obtain more financing funds with lower equity dilution costs, while reducing the difficulty of share issuance by taking advantage of optimistic market expectations at high levels. In essence, it is the optimal balance between corporate equity value and financing efficiency.

To put it simply, the higher the stock price, the lower the company's financing costs.

For example, suppose you want to raise 1 billion yuan. If the stock price is 10 yuan, you would need to issue 100 million shares. However, if the stock price is 1000 yuan, you only need to issue 10 million shares to raise 10 billion yuan. This can protect the equity ratio of existing shareholders, especially the controlling shareholder, to the greatest extent and prevent the dilution of control.

The higher the stock price, the lower the financing cost. Unless a company is foolish, it will raise funds at a relatively high point, which is called a high-level share issuance.

Therefore, as long as there are behaviors such as founders reducing their holdings or issuing new shares, the relationship between volume and price can be ignored, and positions can be reduced in advance to prevent risks.

Upon hearing that Huang Minggui had only given them four days to handle the matter—no, now there were only three and a half days left—Shao ​​Xia immediately looked troubled and said, "Mr. Huang, this matter is a bit tricky. It's not that I don't want to..."

"Can't do it?"

Huang Minggui's tone suddenly turned cold.

Sensing her boss's displeasure, even though she knew it was impossible, Shao Xia could only agree, "We can do it, we can do it."

"That's fine. I just need the results. Also, you guys need to get ready. I'll be going to Jiachen Biotechnology on October 9th," Huang Minggui said, explaining his travel plans.

He genuinely had no idea about Jiachen Biotechnology's vaccine development progress, nor did he understand the treatment principle of the curative hepatitis B vaccine.

But he was well aware that over the past decade, Shancheng Beer had invested over a billion to two billion yuan in Jiachen Biotechnology, hoping to turn the tide with a curative hepatitis B vaccine.

But now?

Trouble keeps piling up!
However, thanks to these troubles, Huang Minggui realized that he could no longer be a hands-off manager and had to personally follow up on the development progress of a curative hepatitis B vaccine.

"No problem, Mr. Huang, I'll arrange it right away. I look forward to your presence then."

Shao Xia said some nice things, but she had already planned her escape route.

Curable hepatitis B vaccine?
all fake!

These are all tricks he uses to swindle money!

Jiachen Bio's so-called synthetic peptide vaccine is actually Cytel's CY-1899 curative hepatitis B vaccine.

In 1998, Cytel and Scripps Research established Sequel Therapeutics, a joint venture focused on the development of therapeutic hepatitis B vaccines.

In early 1999, CY-1899 entered Phase I clinical trials, but the results showed that although the vaccine could activate T-cell responses, its activity level was significantly lower than the threshold required for natural clearance of the hepatitis B virus, and no significant improvement in viral load or liver function was observed.

In 2000, both Cytel and Scripps Research announced that the development of the CY-1899 curative hepatitis B vaccine had failed.

In contrast, the timeline of Jiachen Bio's acquisition by Shancheng Beer was October 27, 1998, which almost overlapped with the timeline of Cytel and the Scripps Research Institute's establishment of Sequel Therapeutics.

Moreover, after 2000, Jiachen Biotechnology announced a series of major breakthroughs in synthetic peptide vaccines, and Shancheng Beer increased its stake from 52% to 93.15%, achieving absolute control.

The person who orchestrated this scam is Shao Xia, the CEO of Jiachen Biotechnology, who has already embezzled hundreds of millions of yuan.

After hanging up Huang Minggui's call, Shao Xia knew she couldn't stay in China any longer. She muttered to herself, "I can't delay any longer. It's the National Day holiday, and no one will suspect anything if I go abroad."

He dared not hesitate for a moment and began his escape operation.

……

And at the same time.

the other side.

Chaos Investment Meeting Room.

The meeting room at this moment was not filled with employees of Chaos Investment, but with all the institutions involved in the development of Shancheng Beer. Among them was Xu Xiang of Zexi Private Equity.

China Asset Management – ​​Wang Yawei.

Li Xuli, founder of Xin Chongyang Private Equity.

Shitong Private Equity – Chang Shishan.

……

He Zhen, GF Fund Management.

Jingfu Private Equity - Chen Shan.

It's no exaggeration to say that the dozen or so people sitting in the conference room right now are the most outstanding private equity and public fund managers of 2009.

Seeing that most people had arrived, Ge Weidong got straight to the point: "To be honest, Mr. J's scheme has far exceeded my expectations. The reason I've gathered everyone here is to get a definite answer: whether or not the smashing will happen after the holiday?"

As online discussions about whether synthetic peptide vaccines have a flawed pathway intensified, Ge Weidong and Song Zijun were unwilling, or rather, dared not, to continue playing dirty tricks with other institutions.

They want to either retreat together or stand together; they want to play their cards openly.

As soon as Ge Weidong finished speaking, everyone in the conference room looked at each other, and then focused their attention on Xu Xiang.

Barring any unforeseen circumstances, Xu Xiang holds the largest number of shares among them, and he is also the one who controls the rise and fall of the stock price.

Seeing all eyes on him, Xu Xiang calmly stated, "It's too early to draw conclusions now. We mainly need to see what Jiachen Biotechnology and Shancheng Beer say."

"The statements from Jiachen Bio and Shancheng Beer are correct, but the online public opinion is almost one-sided right now, and even former employees are coming out to expose the fraud. We also need to reach a consensus."

Wang Yawei immediately responded with a counter-question.

He didn't want to keep drinking Ou Guiyan's soy milk by the side. If they didn't reach a conclusion today, he would be the first to smash the plate and run away.

As the renowned American investment guru Jesse Livermore once said: "Paid-up profits are not money; real profits are. The market will give you a false sense of wealth until you learn to take profits in time."

Although Wang Yawei is a public fund manager, he also has a dream of running a private equity fund.

"Yawei is right."

"A unified approach is indeed needed."

"Yes."

"Manager Wang is right."

The other managers nodded in agreement.

Xu Xiang glanced at Wang Yawei, adopted a humble and eager-to-learn attitude, and asked, "So, according to Manager Wang, what does that mean...?"

"My thinking is very simple." Wang Yawei smiled calmly and said frankly, "Wherever public opinion leans, I will lean in that direction."

The reason he became the top public fund manager was largely due to his understanding of market trends.

The idea that trends are irreversible and will inevitably prevail has permeated his career in the public fund industry.

"Based on the current public opinion trend, the market is likely to be bearish on the 9th. Given the insufficient support at the bottom, it wouldn't be good to sell off, would it?"

Chang Shishan asked in a deep voice.

As a landmark figure in China's private equity industry, he is famous for his original "three-low buying method" and "rolling compound interest method".

The so-called "three-low buying method" focuses on low-priced, low-valuation, and low-attention targets, and waits for their value to be released by making early investments.

The rolling compound interest principle involves combining short-term swing trading with medium-term holdings. The core idea is that all profits from short-term fluctuations are converted into medium-term holdings, achieving compound growth in assets or liabilities through periodic "rolling." Essentially, it is a dynamic interest calculation model of "interest generating interest."

He advocates that "water has no constant shape, and stocks have no constant trend," emphasizing the need to flexibly respond to market changes.

"If the panic spreads to the 9th, there will definitely be a wave of selling pressure in the morning. It would be best if we could absorb the selling pressure first, and then gradually sell off our holdings over a longer period of time," said He Zhen, a public fund manager at GF Fund Management, in a deep voice.

"Since we're going to take over, who will? If we all take over, how should the share be allocated?" Li Xuli, the private equity manager of Xin Chongyang, scanned the crowd, then his gaze fell on Ge Weidong and he said, "If I remember correctly, Chaos Investment seems to have signed a bond lending agreement with Mr. J?"

The meaning of this statement is quite clear: Ge Weidong should bear the lion's share, while others should bear the rest.

Ge Weidong was naturally not going to be taken advantage of, and defended himself by saying, "My settlement date with Mr. J is October 28th. Putting aside the possibility of a near-term price surge, there are still two days' worth of profit margin left, so I don't need to panic too much."

"But..."

He suddenly changed his tune and softened his stance, saying, "If you delay the shipment by seven trading days, I can take on more of the burden, but it can't exceed half."

They had an eight-day holiday at the beginning of October. If we start counting from the 9th, there are only 14 trading days left until the settlement date on the 28th of the month.

According to Ge Weidong, as long as Xu Xiang, Wang Yawei, Chang Shishan, and Li Xuli don't dump shares, retail investors and Mr. J won't be able to cause any trouble.

When the conditions were presented, everyone present fell into deep thought.

Delaying shipment by seven trading days?
Let alone a seven-day delay, even a three-day delay would be unacceptable to them.

Because nobody knows what's really going on with Jiachen Bio's activities related to the Chongqing Beer event, the online public opinion has been unable to be calmed for a long time.

"I need to go back and think about it carefully." Jingfu Private Equity Manager Chen Shan neither agreed nor refused, but left himself room for maneuver.

“Manager Xu is right. Let’s wait for the response first, and then we can make a decision,” He Zhen agreed.

"Then let's wait for their response."

"Let's wait for a response."

"It can only be this way."

Other managers followed suit and expressed their opinions.

Don't be fooled by their polite demeanor on the surface; they're all secretly hoping the other will take over their assets so they can extricate themselves.

……

On October 6th, with only 3 days left before the A-share market opened, Jiachen Bio finally responded to recent questions about its vaccines in the morning after Huang Minggui put pressure on the company.

[To all investors, followers and the public:]

Recently, the market and various parties have raised numerous concerns and questions regarding the therapeutic hepatitis B vaccine (hereinafter referred to as "the vaccine") jointly developed by our company and the Third Military Medical University. As the main body responsible for the research and development of the project, Jiachen Biotechnology has always adhered to a rigorous scientific approach in advancing the work. The core concerns are addressed as follows:
1. The clinical trials of this vaccine strictly followed the international standard procedure of "multicenter, randomized, double-blind, placebo-controlled", and all protocols were approved by the National Medical Products Administration and reviewed by the ethics committee.

2. The vaccine uses a synthetic peptide technology route, which aims to activate the immune response by precisely targeting HBV antigen epitopes. This route has a clear theoretical basis in the field of viral infectious disease treatment.

3. The core objective of therapeutic hepatitis B vaccines is to activate the body's specific T-cell response to clear the virus. This is a technical challenge in the global biomedical field. The immunogenicity data of our company's vaccine is still under continuous monitoring, and the final conclusion needs to be confirmed by statistical analysis after all clinical trials are completed.

4. The Phase II clinical trial of the combination therapy group is currently progressing according to the planned schedule. The trial period is 96 weeks, and it is expected that all clinical observations and specimen testing will be completed in early 2013. The current progress is consistent with the previous announcement and there is no "delay in progress".

Since collaborating with the Third Military Medical University in 1998, Jiachen Biotechnology has consistently aimed to overcome the challenges of hepatitis B treatment, adhering to scientific principles and compliance standards. We understand the concerns of all parties regarding the project and will continue to respond to market inquiries in an open and transparent manner. We thank the public for their supervision and support.
After working overtime all night, this response announcement was quite well done.

Bing Yaojie originally wanted to use international literature data to question the rigor of Jiachen Bio's experimental design, but the other party responded that it had been approved by the National Medical Products Administration.

Still questioning?
You still dare to question that?

The second and third points both demonstrate the feasibility of the technology, and the phrase at the end of the third point, "it needs to be confirmed by statistical analysis after all clinical trials are completed," is an attempt to delay the process.

What does Jiachen Biotech need most right now?
time!

As the saying goes, time is like a pot of warm water, which can dilute everything in the world!
Anyone who frequently uses the internet knows that if something isn't resolved immediately and is left unresolved for a few days, netizens will forget about it, and few people will pay attention to it afterward.

This is why many public relations teams try to delay things as much as possible when they are doing emergency public relations work, allowing the public opinion to gradually fade away and eventually disappear.

The fourth point further illustrates the "delaying tactic," directly providing everyone with a forward-looking guide for 2013.

Public opinion from 2009 couldn't possibly continue into 2013, could it?

That's practically impossible!

When Jiachen Bio issued its announcement, a large number of shareholders who had bought shares in Shancheng Beer spontaneously gathered to "fight" for their wallets.

[Flashing]: Don't believe or spread rumors. Jiachen Biotechnology's R&D technology roadmap is well-founded and its processes comply with national regulations. Do not listen to rumors spread by others!

[Favorite Black-Footed Cat]: Jiachen Bio is an excellent domestic biopharmaceutical company with strong R&D capabilities. Our peers should not smear excellent companies for their own selfish reasons!
[White Silk Shao Yu]: To protect Jiachen Biotechnology and millions of hepatitis B patients, we need a curative hepatitis B vaccine.

[I'm so awesome]: Tiantan Biological, Hualan Biological, Da'an Gene, and Huahai Pharmaceutical are engaging in unscrupulous competition. I have already reported them to the security department. These companies may be spies, specifically targeting and defaming our domestic enterprises.

With retail investors chiming in, Jiachen Bio's online reputation seems to have undergone a complete 180-degree reversal in an instant.

Many students majoring in pharmaceutical research saw the latest response announcement and vaguely felt that it made some sense, but they couldn't quite put their finger on what was wrong with it.

Seeing that public opinion was shifting, Xu Xiang's partner, Ma Xinqi of the Ningbo Limit-Up Daredevil Team, immediately contacted a large number of financial media outlets and began to distort retail investors' understanding of the event.

"Injustice Recovered! Synthetic Peptide Vaccines Prove to Have Sound Technical Basis After Multiple Targeted Exposés!"

Is there a power struggle among multiple capital groups? Jiachen Bio has suffered its largest and most participated-in smear campaign in history!

Synthetic peptide vaccines have been tested and proven effective! Jiachen Biotechnology issues its latest response, stating that all procedures comply with regulations and welcomes verification!

After the three tactics of online trolls confusing the public, self-media polluting the page, and paying for clicks to increase popularity, a large number of retail investors have been fooled to the point of being unable to tell which way is which.

Clicking on Weibo's trending topics, you can still see the entry "Synthetic peptide vaccine confirmed to be real." For retail investors who are slow to get information, they might really go all in after the holiday!
……

October 8th is the last day of the holiday that overlaps with the National Day and Mid-Autumn Festival.

After Jiachen Bio issued a statement on October 6th to refute the rumors, coupled with the threat of a lawyer's letter from the legal department of Shancheng Beer, most of the doubts about the synthetic peptide vaccine disappeared throughout the day on October 7th. Many students majoring in pharmaceutical research, even if they still had questions, dared not speak out due to the threat of the lawyer's letter.

As for pharmaceutical company executives such as Qiao Lechen, Bing Yaojie, and He Jiani, they thought that their task was completed after making their statements.

As everyone knows!
Their mission is far from over!
"Ding-dong-"

"Ladies and gentlemen, our plane is about to land at Shanghai Hongqiao Airport. Please immediately adjust your seat backs to an upright position, stow your tray tables and footrests, and double-check that your seatbelts are fastened securely. There may be slight turbulence during the descent, so please remain seated throughout the flight. Thank you for your cooperation."

Zhang Yang, sitting in first class, didn't move, because straightening the seat was only for economy class, and Zhang Yang's phone was still connected to the internet, still browsing Weibo. This was the privilege that could be enjoyed by paying more money.

Moreover, when the announcement sounded, the flight attendant quickly came to Zhang Yang's side and said, "Mr. Zhang, our plane is about to land. If you need anything, you can press the call button next to you."

"Give me a bottle of mineral water."

Zhang Yang said calmly.

"Okay, Mr. Zhang." The flight attendant replied and hurried to get the bottled water.

Not a moment.

The flight attendant turned back and handed the Yibao mineral water to Zhang Yang.

"Mr. Zhang, here's your water."

"Thank you."

"You're welcome. Just press the bell if you need anything."

"it is good."

After a brief conversation, the flight attendant returned to her seat.

Zhang Yang took a sip of mineral water, taking in the online public opinion trends. He muttered to himself, "The hype surrounding synthetic peptide vaccines has been thoroughly heated, and the battle against counterfeits has been deeply ingrained in the minds of retail investors. It's time to close the net."

Whether it's Li Xiangwen's real-name video whistleblowing, or the comebacks of company executives like Qiao Lechen, Bing Yaojie, and He Jiani to expose the fraud, or the debate among pharmaceutical research students about research pathways, all of these events highlight the potential problems with Jiachen Bio's synthetic peptide vaccine.

They were like Duke Zhuang of Zheng shooting the Zhou emperor with an arrow. From the moment the god shed the first drop of blood, he was no longer a god. The prestige of the Zhou royal family among the vassal states also plummeted to freezing point, heralding the official arrival of the Spring and Autumn Period!

Guided step by step, gradually, first branding synthetic peptide vaccines with problematic labels, and finally revealing their true nature, completely debunking the cure for hepatitis B!
As the plane arrived at Hongqiao Airport, Zhang Yang quickly left the airport.

Back on the Caiyan.com office platform, he immediately used his computer to send a final, decisive email to Qiao Lechen, Bing Yaojie, He Jiani, and other senior executives of the company.

"Ding--"

Qiao Lechen, far away in Yanjing, saw an email notification pop up in the lower right corner of his computer. It was from the email address of "Mr. J". He didn't dare to be negligent at all and quickly opened the email to check it.

Thank you all for your cooperation. Now, there's one last thing we need your help with. If completed successfully, all recordings and evidence related to suspected insider trading will be destroyed. Now, please open the attachment in this email, process its contents, and expose this 10-year scam!
"A 10-year scam?"

Qiao Lechen's heart skipped a beat.

He quickly downloaded the attachment.

When the attachment finished downloading, the moment he opened the document, a string of large words caught his eye: Jiachen Biosynthetic Peptide Vaccine is Cytel's failed CY-1899 vaccine!

　Reader 0008278 has won a prize! Please check your account and contact me to claim your prize. Your September monthly votes are 14,000. Starting October 1st, I will be sending out 10,000 recommendation votes as a bonus for 10 consecutive days. Also, on the 1st at noon, I will be sending out a 500 yuan bonus in the group.

　　
　
(End of this chapter)